In conclusion, our study shows that combined marker profiling is more sensitive at detecting subtle shifts in EV subpopulations than considering only single markers and that elevated FASN+/CD63+ as well as FASN+/CD81+ EVs are characteristic of glioma patients and may help to distinguish them from healthy individuals. This evidence concerns the gene FASN and central nervous system cancer.